Principal Financial Group® Announces Reinsurance Transaction, Increases Share Repurchase Authorization by $1.6 Billion
Announces agreement to reinsure its in-force U.S. retail fixed annuity and universal life insurance with…
Announces agreement to reinsure its in-force U.S. retail fixed annuity and universal life insurance with…
LOGIX’s robust network supports major carriers across Texas as they launch 5G HOUSTON–(BUSINESS WIRE)–#businessinternet—LOGIX Fiber…
Ms. Currie Brings Vast Experience Developing and Implementing Marketing Strategies to Drive Growth in Categories…
Syniverse’s Evolved Mobility Enables New Roaming Capabilities for Verizon TAMPA, Fla.–(BUSINESS WIRE)–#evolvedmobility—Syniverse, the “world’s most…
Article in Nature Explains the Application of Physics-Aware Training Algorithm and Shares Results of Tests…
Company to Showcase its InMotion® Arm/Hand at the Country’s Largest Physical Therapy Conference from February…
COLUMBIA, Md.–(BUSINESS WIRE)–BigBear.ai (NYSE: BBAI), a leading provider of artificial intelligence (“AI”), machine learning, cloud-based…
Out-of-home (OOH) advertising startup marks various milestones as it preps to expand on the first-of-its-kind…
Payoneer’s 2022 Global Freelancer Income Report reveals that the worldwide average hourly freelance rate has…
TROY, Mich.–(BUSINESS WIRE)–J.D. Power, a global leader in data analytics and consumer intelligence, today announced…
COLUMBIA, Md.–(BUSINESS WIRE)–Corporate Office Properties Trust (“COPT” or the Company) (NYSE: OFC) announced the 2021…
San Francisco, January 31, 2022 – MPC Alliance has started the year by appointing new…
Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved…
BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late…
Synopsis of 2021 Achievements and Key Activities for 2022 CALGARY, Alberta, Jan. 31, 2022 (GLOBE…
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company…
Enrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022 GAITHERSBURG, Md.,…
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology…
TORONTO and HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the…
– VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume…